Literature DB >> 21844006

Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice.

Richard D Moore1, John G Bartlett.   

Abstract

BACKGROUND: We have previously showed that as antiretroviral therapy has improved over time since 1995-1996, the likelihood of achieving virologic suppression has also improved. Antiretroviral therapy and antiretroviral therapy guidelines have continued to evolve, and we wished to determine the trend in human immunodeficiency virus (HIV-1) RNA levels over time in HIV-infected persons receiving care in our large urban HIV clinical practice in Baltimore, Maryland.
METHODS: The HIV-1 RNA level was assessed each year from 1996 through 2010 at the date closest to 1 July for all patients in care and followed up in the Johns Hopkins HIV Clinical Cohort. The clinic population's median HIV-1 RNA level and stratified threshold levels were plotted. The demographic characteristics of the population were also assessed over time.
RESULTS: From 1996 (shortly after highly active antiretroviral therapy [HAART] was introduced) to 2010, the median HIV-1 RNA level decreased from 10,400 to <200 copies/mL. The proportion of patients with an HIV-1 RNA level >500 copies/mL decreased from 75% to only 16% during this same period. The population itself became older, had a higher proportion of women, and a lower proportion of patients with injection drug use as a transmission risk, but it was geographically stable. There was an increase in HAART use over time. DISCUSSION: Our results demonstrate the remarkable impact of increased use of and improved management with HAART in this urban HIV-infected population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844006      PMCID: PMC3202317          DOI: 10.1093/cid/cir467

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

Authors:  R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.

Authors:  Richard D Moore; Jeanne C Keruly; Kelly A Gebo; Gregory M Lucas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-06-01       Impact factor: 3.731

3.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Authors:  Reuben M Granich; Charles F Gilks; Christopher Dye; Kevin M De Cock; Brian G Williams
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

4.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort.

Authors:  R D Moore
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

5.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

6.  Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-12-03       Impact factor: 17.586

7.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.

Authors:  Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark
Journal:  MMWR Recomm Rep       Date:  2006-09-22

8.  Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

Authors:  G M Lucas; R E Chaisson; R D Moore
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

Review 9.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.

Authors:  Suzanna Attia; Matthias Egger; Monika Müller; Marcel Zwahlen; Nicola Low
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

10.  Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006.

Authors:  Jeanne C Keruly; Richard D Moore
Journal:  Clin Infect Dis       Date:  2007-10-11       Impact factor: 9.079

View more
  28 in total

1.  Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?

Authors:  Rajesh T Gandhi; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

2.  Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age.

Authors:  Rajesh T Gandhi; Paul E Sax; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

3.  Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island.

Authors:  Francine Touzard Romo; Fizza S Gillani; Peter Ackerman; Aadia Rana; Erna M Kojic; Curt G Beckwith
Journal:  R I Med J (2013)       Date:  2014-01-05

4.  Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.

Authors:  Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan
Journal:  AIDS Behav       Date:  2017-04

5.  Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Pavan Kumar Prathipati; Subhra Mandal; Christopher J Destache
Journal:  J Pharm Biomed Anal       Date:  2016-07-26       Impact factor: 3.935

6.  Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy.

Authors:  E Sezgin; M L Van Natta; J E Thorne; M A Puhan; D A Jabs
Journal:  HIV Med       Date:  2018-03-24       Impact factor: 3.180

7.  The Association Between Changes in Alcohol Use and Changes in Antiretroviral Therapy Adherence and Viral Suppression Among Women Living with HIV.

Authors:  Nikita Barai; Anne Monroe; Catherine Lesko; Bryan Lau; Heidi Hutton; Cui Yang; Anika Alvanzo; Mary Elizabeth McCaul; Geetanjali Chander
Journal:  AIDS Behav       Date:  2017-07

8.  Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.

Authors:  Sonia Napravnik; Joseph J Eron; Timothy R Sterling; Timothy Juday; Jonathan Uy; Richard D Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-12       Impact factor: 2.205

9.  Improvements in the continuum of HIV care in an inner-city emergency department.

Authors:  Gabor D Kelen; Yu-Hsiang Hsieh; Richard E Rothman; Eshan U Patel; Oliver B Laeyendecker; Mark A Marzinke; William Clarke; Teresa Parsons; Jordyn L Manucci; Thomas C Quinn
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

10.  Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.

Authors:  Ryan P Westergaard; Timothy Hess; Jacquie Astemborski; Shruti H Mehta; Gregory D Kirk
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.